Children's Cancer Institute, Sydney, NSW, Australia.

OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynt...

Published in Leukemia

Effective treatment of some types of cancer can be achieved by modulating cell lineage-specific rather than tumor-specific targets. We conducted a systematic search for novel agents selectively toxic to cells of hematopoietic origin. Chemical library screenings followed by hit-to-lead optimization identified OT-82, a small molecule with strong effi...